{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:57:56Z","timestamp":1774601876053,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10490-6","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:38:42Z","timestamp":1738215522000},"page":"565-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sodium zirconium cyclosilicate for MRAs optimization in HFrEF: lessons learned from the REALIZE-K trial"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2958-943X","authenticated-orcid":false,"given":"Luca","family":"Monzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Musella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"10490_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709\u2013717. https:\/\/doi.org\/10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"10490_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"10490_CR3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321. https:\/\/doi.org\/10.1056\/NEJMoa030207","journal-title":"N Engl J Med"},{"key":"10490_CR4","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/ejhf.2986","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Huttin O, Ferreira JP et al (2023) Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: the REMI study. Eur J Heart Fail 25:1742\u20131752. https:\/\/doi.org\/10.1002\/ejhf.2986","journal-title":"Eur J Heart Fail"},{"key":"10490_CR5","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","volume":"62","author":"R Eschalier","year":"2013","unstructured":"Eschalier R, McMurray JJ, Swedberg K et al (2013) Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 62:1585\u20131593. https:\/\/doi.org\/10.1016\/j.jacc.2013.04.086","journal-title":"J Am Coll Cardiol"},{"key":"10490_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","volume":"7","author":"O Vardeny","year":"2014","unstructured":"Vardeny O, Claggett B, Anand I et al (2014) Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7:573\u2013579. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001104","journal-title":"Circ Heart Fail"},{"key":"10490_CR7","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/ejhf.3049","volume":"25","author":"F Guidetti","year":"2023","unstructured":"Guidetti F, Lund LH, Benson L et al (2023) Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from Swedish Heart Failure Registry. Eur J Heart Fail 25:2164\u20132173. https:\/\/doi.org\/10.1002\/ejhf.3049","journal-title":"Eur J Heart Fail"},{"key":"10490_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/HJH.0000000000002275","volume":"38","author":"L Monzo","year":"2020","unstructured":"Monzo L, Ferreira JP, Abreu P et al (2020) Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. J Hypertens 38:420\u2013425. https:\/\/doi.org\/10.1097\/HJH.0000000000002275","journal-title":"J Hypertens"},{"key":"10490_CR9","doi-asserted-by":"publisher","unstructured":"Monzo L, Bresso E, Dickstein K, Pitt B, Cleland JGF, Anker SD, Lam CSP, Mehra MR, van Veldhuisen DJ, Greenberg B, Zannad F, Girerd N\u00a0(2024)\u00a0Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3547","DOI":"10.1002\/ejhf.3547"},{"key":"10490_CR10","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ejhf.2952","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Girerd N, Duarte K et al (2023) Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from the EMPHASIS-HF trial. Eur J Heart Fail 25:1444\u20131449. https:\/\/doi.org\/10.1002\/ejhf.2952","journal-title":"Eur J Heart Fail"},{"key":"10490_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","volume":"9","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Verdonschot J, Wang P et al (2021) Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC Heart Fail 9:268\u2013277. https:\/\/doi.org\/10.1016\/j.jchf.2020.11.010","journal-title":"JACC Heart Fail"},{"key":"10490_CR12","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1002\/ehf2.14086","volume":"9","author":"L Monzo","year":"2022","unstructured":"Monzo L, Ferreira JP, Cleland JGF et al (2022) Dyskalemia in people at increased risk for heart failure: findings from the heart \u2018OMics\u2019 in AGEing (HOMAGE) trial. ESC Heart Fail 9:4352\u20134357. https:\/\/doi.org\/10.1002\/ehf2.14086","journal-title":"ESC Heart Fail"},{"key":"10490_CR13","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:1757\u20131780. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011","journal-title":"J Am Coll Cardiol"},{"key":"10490_CR14","doi-asserted-by":"publisher","unstructured":"Authors\/Task Force M, McDonagh TA, Metra M et al (2022) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24:4-131. https:\/\/doi.org\/10.1002\/ejhf.2333","DOI":"10.1002\/ejhf.2333"},{"key":"10490_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM et al (2018) Medical Therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll Cardiol 72:351\u2013366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"key":"10490_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamacardio.2023.0241","volume":"8","author":"JB Pierce","year":"2023","unstructured":"Pierce JB, Ikeaba U, Peters AE et al (2023) Quality of care and outcomes among patients hospitalized for heart failure in rural vs urban us hospitals: the get with the guidelines-Heart Failure Registry. JAMA Cardiol 8:376\u2013385. https:\/\/doi.org\/10.1001\/jamacardio.2023.0241","journal-title":"JAMA Cardiol"},{"key":"10490_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543\u2013551. https:\/\/doi.org\/10.1056\/NEJMoa040135","journal-title":"N Engl J Med"},{"key":"10490_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H et al (2018) Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail 20:1217\u20131226. https:\/\/doi.org\/10.1002\/ejhf.1199","journal-title":"Eur J Heart Fail"},{"key":"10490_CR19","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/ejhf.1793","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol P, Lainscak M, Crespo-Leiro MG et al (2020) Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 22:1378\u20131389. https:\/\/doi.org\/10.1002\/ejhf.1793","journal-title":"Eur J Heart Fail"},{"key":"10490_CR20","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","volume":"75","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Butler J, Rossignol P et al (2020) Abnormalities of potassium in heart failure: JACC state-of-the-art review. J Am Coll Cardiol 75:2836\u20132850. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.021","journal-title":"J Am Coll Cardiol"},{"issue":"264","key":"10490_CR21","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/j.amjmed.2012.08.016","volume":"126","author":"Z Harel","year":"2013","unstructured":"Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM (2013) Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 126(264):e269\u2013e224. https:\/\/doi.org\/10.1016\/j.amjmed.2012.08.016","journal-title":"Am J Med"},{"key":"10490_CR22","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/ckj\/sfad090","volume":"16","author":"P Rossignol","year":"2023","unstructured":"Rossignol P, Pitt B (2023) Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere! Clin Kidney J 16:1221\u20131225. https:\/\/doi.org\/10.1093\/ckj\/sfad090","journal-title":"Clin Kidney J"},{"key":"10490_CR23","doi-asserted-by":"publisher","first-page":"A55","DOI":"10.1093\/eurheartj\/suy034","volume":"21","author":"F Zannad","year":"2019","unstructured":"Zannad F, Ferreira JP, Pitt B (2019) Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments. Eur Heart J Suppl 21:A55\u2013A60. https:\/\/doi.org\/10.1093\/eurheartj\/suy034","journal-title":"Eur Heart J Suppl"},{"key":"10490_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA et al (2015) Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372:211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1410853","journal-title":"N Engl J Med"},{"key":"10490_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Pitt B, Weir MR et al (2015) Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 314:151\u2013161. https:\/\/doi.org\/10.1001\/jama.2015.7446","journal-title":"JAMA"},{"key":"10490_CR26","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rossignol P, Romero A et al (2019) Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 394:1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(19)32135-X","journal-title":"Lancet"},{"key":"10490_CR27","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P et al (2014) Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312:2223\u20132233. https:\/\/doi.org\/10.1001\/jama.2014.15688","journal-title":"JAMA"},{"key":"10490_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT et al (2015) Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 372:222\u2013231. https:\/\/doi.org\/10.1056\/NEJMoa1411487","journal-title":"N Engl J Med"},{"key":"10490_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.11.014","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Cherney DZI, Desai AS et al (2024) Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.014","journal-title":"J Am Coll Cardiol"},{"key":"10490_CR30","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jchf.2024.05.003","volume":"12","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Cherney D, Connelly K et al (2024) Sodium zirconium cyclosilicate in HFrEF and hyperkalemia: REALIZE-K design and baseline characteristics. JACC Heart Fail 12:1707\u20131716. https:\/\/doi.org\/10.1016\/j.jchf.2024.05.003","journal-title":"JACC Heart Fail"},{"key":"10490_CR31","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA et al (2011) Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32:820\u2013828. https:\/\/doi.org\/10.1093\/eurheartj\/ehq502","journal-title":"Eur Heart J"},{"key":"10490_CR32","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/ejhf.1860","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol P, Williams B, Mayo MR et al (2020) Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. Eur J Heart Fail 22:1462\u20131471. https:\/\/doi.org\/10.1002\/ejhf.1860","journal-title":"Eur J Heart Fail"},{"key":"10490_CR33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F et al (2015) Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 17:1050\u20131056. https:\/\/doi.org\/10.1002\/ejhf.300","journal-title":"Eur J Heart Fail"},{"key":"10490_CR34","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ehf2.14268","volume":"10","author":"JC Tardif","year":"2023","unstructured":"Tardif JC, Rouleau J, Chertow GM et al (2023) Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Fail 10:1066\u20131076. https:\/\/doi.org\/10.1002\/ehf2.14268","journal-title":"ESC Heart Fail"},{"key":"10490_CR35","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Lund LH et al (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 43:4362\u20134373. https:\/\/doi.org\/10.1093\/eurheartj\/ehac401","journal-title":"Eur Heart J"},{"key":"10490_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000504078","volume":"50","author":"SD Roger","year":"2019","unstructured":"Roger SD, Spinowitz BS, Lerma EV et al (2019) Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE. Am J Nephrol 50:473\u2013480. https:\/\/doi.org\/10.1159\/000504078","journal-title":"Am J Nephrol"},{"key":"10490_CR37","doi-asserted-by":"publisher","unstructured":"Desai NR, Kammerer J, Budden J, Olopoenia A, Tysseling A, Gordon A (2024) The association of heart failure and edema events between patients initiating SZC or patiromer. Kidney360. https:\/\/doi.org\/10.34067\/KID.0000000586","DOI":"10.34067\/KID.0000000586"},{"key":"10490_CR38","unstructured":"Geneva World Health Organization (2012).\u00a0Guidelines: Sodium intake for adults and children.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK133309\/"},{"key":"10490_CR39","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1093\/eurheartj\/ehac399","volume":"43","author":"M Packer","year":"2022","unstructured":"Packer M (2022) Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial. Eur Heart J 43:4374\u20134377. https:\/\/doi.org\/10.1093\/eurheartj\/ehac399","journal-title":"Eur Heart J"},{"key":"10490_CR40","doi-asserted-by":"publisher","first-page":"C309","DOI":"10.1093\/eurheartjsupp\/suad055","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Ferrari I, Cicogna F et al (2023) Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians. Eur Heart J Suppl 25:C309\u2013C315. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad055","journal-title":"Eur Heart J Suppl"},{"key":"10490_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","volume":"2","author":"AS Desai","year":"2017","unstructured":"Desai AS, Vardeny O, Claggett B et al (2017) Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol 2:79\u201385. https:\/\/doi.org\/10.1001\/jamacardio.2016.4733","journal-title":"JAMA Cardiol"},{"key":"10490_CR42","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","volume":"77","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Zannad F, Pocock SJ et al (2021) Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced. J Am Coll Cardiol 77:1397\u20131407. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.044","journal-title":"J Am Coll Cardiol"},{"key":"10490_CR43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","volume":"9","author":"L Shen","year":"2021","unstructured":"Shen L, Kristensen SL, Bengtsson O et al (2021) Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail 9:254\u2013264. https:\/\/doi.org\/10.1016\/j.jchf.2020.11.009","journal-title":"JACC Heart Fail"},{"key":"10490_CR44","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34:2453\u20132463. https:\/\/doi.org\/10.1093\/eurheartj\/eht187","journal-title":"Eur Heart J"},{"key":"10490_CR45","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475\u20131485. https:\/\/doi.org\/10.1056\/NEJMoa2407107","journal-title":"N Engl J Med"},{"key":"10490_CR46","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"key":"10490_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, McMurray JJ et al (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7:51\u201358. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000792","journal-title":"Circ Heart Fail"},{"key":"10490_CR48","doi-asserted-by":"publisher","first-page":"883911","DOI":"10.3389\/fcvm.2022.883911","volume":"9","author":"L Monzo","year":"2022","unstructured":"Monzo L, Reichenbach A, Al-Hiti H et al (2022) Pulmonary vasculature responsiveness to phosphodiesterase-5A inhibition in heart failure with reduced ejection fraction: possible role of plasma potassium. Front Cardiovasc Med 9:883911. https:\/\/doi.org\/10.3389\/fcvm.2022.883911","journal-title":"Front Cardiovasc Med"},{"key":"10490_CR49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/ejhf.1400","volume":"21","author":"JP Ferreira","year":"2019","unstructured":"Ferreira JP, Abreu P, McMurray JJV et al (2019) Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. Eur J Heart Fail 21:345\u2013351. https:\/\/doi.org\/10.1002\/ejhf.1400","journal-title":"Eur J Heart Fail"},{"key":"10490_CR50","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","volume":"46","author":"B Pitt","year":"2005","unstructured":"Pitt B, White H, Nicolau J et al (2005) Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46:425\u2013431. https:\/\/doi.org\/10.1016\/j.jacc.2005.04.038","journal-title":"J Am Coll Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10490-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10490-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10490-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:14:20Z","timestamp":1744359260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10490-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["10490"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10490-6","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"15 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.M. reports grant from Boehringer. N.G. reports honoraria from AstraZeneca, Bayer, Boehringer, Lilly, Novartis, NovoNordisk, Roche Diagnostics, NP Medical and Echosens. P.R. was a DIAMOND and AMBER trial steering committee member. He has received grants and personal fees from AstraZeneca, Bayer, CVRx, Fresenius, and Novartis; and personal fees from Grunenthal, Servier, Stealth Peptides, Vifor Fresenius Medical Care Renal Pharma, Idorsia, NovoNordisk, Ablative Solutions, G3P, Corvidia, and Relypsa. All other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}